Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

638 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S, Shirasawa M, Fukui T, Nishinarita N, Sone H, Ozawa T, Sugita K, Okuma Y, Kurahayashi S, Ono T, Sugimoto A, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K. Igawa S, et al. Among authors: katagiri m. Oncology. 2018;94(4):207-214. doi: 10.1159/000486038. Epub 2018 Jan 31. Oncology. 2018. PMID: 29393275
Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.
Yanaihara T, Yokoba M, Onoda S, Yamamoto M, Ryuge S, Hagiri S, Katagiri M, Wada M, Mitsufuji H, Kubota M, Arai S, Kobayashi H, Yanase N, Abe T, Masuda N. Yanaihara T, et al. Among authors: katagiri m. Cancer Chemother Pharmacol. 2007 Mar;59(4):419-27. doi: 10.1007/s00280-006-0279-5. Epub 2006 Jul 11. Cancer Chemother Pharmacol. 2007. PMID: 16832665 Clinical Trial.
Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer.
Igawa S, Ryuge S, Fukui T, Otani S, Kimura Y, Katono K, Takakura A, Kubota M, Mitsufuji H, Katagiri M, Yanase N, Masuda N. Igawa S, et al. Among authors: katagiri m. Int J Clin Oncol. 2010 Oct;15(5):447-52. doi: 10.1007/s10147-010-0085-2. Epub 2010 May 13. Int J Clin Oncol. 2010. PMID: 20464623
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
Asakuma M, Yamamoto M, Wada M, Ryuge S, Katono K, Yokoba M, Fukui T, Takakura A, Otani S, Maki S, Igawa S, Yanaihara T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Masuda N. Asakuma M, et al. Among authors: katagiri m. Cancer Chemother Pharmacol. 2012 Jun;69(6):1529-36. doi: 10.1007/s00280-012-1858-2. Epub 2012 Mar 14. Cancer Chemother Pharmacol. 2012. PMID: 22415148 Clinical Trial.
Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Otani S, Hamada A, Sasaki J, Wada M, Yamamoto M, Ryuge S, Takakura A, Fukui T, Yokoba M, Mitsufuji H, Toyooka I, Maki S, Kimura M, Hayashi N, Ishihara M, Kasajima M, Hiyoshi Y, Katono K, Asakuma M, Igawa S, Kubota M, Katagiri M, Saito H, Masuda N. Otani S, et al. Among authors: katagiri m. Am J Clin Oncol. 2015 Aug;38(4):405-10. doi: 10.1097/COC.0b013e3182a2d98d. Am J Clin Oncol. 2015. PMID: 26214085 Clinical Trial.
638 results